Navigation Links
Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com
Date:1/6/2014

London, UK (PRWEB) January 06, 2014

Nowadays, molecular diagnostics (MD) represents a promising area of research and medicine, which is witnessing tremendous technology advancements alongside the emergence of novel applications. The range of technologies associated with MD includes, amid others, gene expression profiling using microarrays, DNA probes, next-generation signal detection, first-generation amplification, fluorescent in-situ hybridization (FISH), second-generation microfluidics and biochips, and biosensors and molecular labels. These technologies are essential tools playing vital roles in the optimization of drug therapy, in the discovery of new therapeutic molecules for cancer as well as in the screening, classification and diagnosis of cancer patients. Presently, MD for cancer testing is deemed as the most lucrative area for innovations and growth.

The pool of MD industry players includes but is not limited to CombiMatrix Corporation, LabCorp, Rosetta Genomics, Biodesix, Nuvera Biosciences, Targeted Molecular Diagnostics, Exact Sciences Corporation, bioTheranostics, InterGenetics, Orion Genomics, Sequenom, SABiosciences Corporation, Cancer Genetics and Nuvera Biosciences.

In-demand research report “Molecular Diagnostics in Cancer Testing” drawn up by TriMark Publications LLC (TriMark) has been recently published by Market Publishers Ltd.

Report Details:

Title: Molecular Diagnostics in Cancer Testing
Published: November, 2013
Pages: 232
Price: US$ 3,400.00
http://marketpublishers.com/report/in_vitro_diagnostics/molecular_diagnostics/molecular-diagnostics-in-cancer-testing.html

The research study presents a comprehensive analysis of the MD field with a particular focus on the MD tests for cancer. It uncovers valuable information on the size and growth prospects of the MD market in its cancer detection and therapy applications; provides a thorough examination of the major factors influencing the development of the overall market and its certain segments, and also discloses sales statistics. The report presents description of the actual market state along with insights into the historical evolution of the sector, pinpoints the top market opportunities, covers the regulative framework, offers a snapshot of the existing MD technologies used for cancer testing applications as well as presents a summary of the recent business activities in the field. The study delves into the competitive landscape, unveils valuable data on the key market participants, and also contains forecasts for the MD market development in the next 5 years.

Report Features & Benefits:

  •     Extensive introduction to MD (insights into the historical background, a description of the current market landscape and a review of the market opportunities).
  •     Comprehensive analysis of the overall cancer diagnostics molecular testing market.
  •     Snapshot of the sales and marketing strategies.
  •     Examination of the competitive environment.
  •     Summary of the existing technologies used for cancer testing applications.
  •     Evaluation of the business environment, data on the recent business activities and SWOT comparison of business models.
  •     Characterization of the top market trends.
  •     Important information on the government regulations.
  •     Discussion of various business decisions using MD tests in cancer testing.
  •     Detailed company profiles.
  •     Five-year outlook for the MD market.

More insightful research reports by TriMark can be found at http://marketpublishers.com/members/trimark/info.html.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11464364.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
2. Molecular probes identify changes in fibronectin that may lead to disease
3. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
4. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
5. Scientists discover distinct molecular subtype of prostate cancer
6. New molecular structure offers first picture of a protein family vital to human health
7. Grb2 holds powerful molecular signaling pathway in check
8. Better treatment for brain cancer revealed by new molecular insights
9. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
10. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
11. Molecular switch identified that controls key cellular process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... ... Konur, CEO of Cardiovascular Institute of the South announced today that Dr. Robert ... live case of an Intravascular Ultrasound Guided Coronary Atherectomy. , This ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and ... to the impact our aging population has on communities and resources. Aging Life Care ... for and face age-related challenges. , Aging Life Care is a holistic, client-centered ...
(Date:5/5/2016)... Chicago, Illinois (PRWEB) , ... May 05, 2016 ... ... published its “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit ... as a “tobacco product,” apply to all vaping products that entered the market ...
(Date:5/5/2016)... ... ... from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team Semper ... Mountain Bike Camp, hosted in conjunction with WTB and Cannondale in ... who’ll share pro tips with the injured veterans as they rip down some of the ...
(Date:5/5/2016)... , ... May 05, 2016 , ... LELO ... self-love. Every day, LELO fans reach out via email, social media and on the ... upcoming up: “Is the way I masturbate ‘normal’ or ‘correct’?” , While some methods ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocytopenia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocytopenia Market and ... comprehensive insights into Thrombocytopenia pipeline products, ...
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
Breaking Medicine Technology: